Arcutis Biotherapeutics
ARQT
188 hedge funds and large institutions have $1.2B invested in Arcutis Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 73 increasing their positions, 48 reducing their positions, and 31 closing their positions.
490% more call options, than puts
Call options by funds: $5.83M | Put options by funds: $989K
52% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 48
1% more funds holding
Funds holding: 186 → 188 (+2)
6% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 31
2% more capital invested
Capital invested by funds: $1.18B → $1.2B (+$21.7M)
0.77% more ownership
Funds ownership: 109.28% → 110.05% (+0.77%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$11.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.08M |
| 3 |
SC
Stempoint Capital
New York
|
+$8.02M |
| 4 |
Goldman Sachs
New York
|
+$7.72M |
| 5 |
D.E. Shaw & Co
New York
|
+$7.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.7M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$9.59M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$7.79M |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$5.69M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$4.55M |
ARQT Hedge Fund Activity: Q3 2024 in Review
188 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q3 2024, worth a combined $1.2B — up 1.8% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ARQT positions and 31 closed out — a net gain of 2 holders — while 73 added to existing stakes and 48 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $11.3M. The largest seller was Deutsche Bank, cutting an estimated $10.7M.
- 188 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q3 2024, up from 186 in Q2 2024.
- Funds reported $1.2B of Arcutis Biotherapeutics stock for Q3 2024, up 1.8% quarter-over-quarter.
- 33 funds opened new Arcutis Biotherapeutics positions in Q3 2024 and 31 closed out, a net change of +2 holders.
- The largest Arcutis Biotherapeutics buyer in Q3 2024 was Rubric Capital Management (New York), an estimated $11.3M added.
- The largest Arcutis Biotherapeutics seller in Q3 2024 was Deutsche Bank, an estimated $10.7M sold.
Based on aggregated 13F filings for Q3 2024.